CN117323250A - Skin care composition and use thereof - Google Patents
Skin care composition and use thereof Download PDFInfo
- Publication number
- CN117323250A CN117323250A CN202311445031.3A CN202311445031A CN117323250A CN 117323250 A CN117323250 A CN 117323250A CN 202311445031 A CN202311445031 A CN 202311445031A CN 117323250 A CN117323250 A CN 117323250A
- Authority
- CN
- China
- Prior art keywords
- skin
- care composition
- skin care
- promoting
- raspberry ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 claims abstract description 36
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000001737 promoting effect Effects 0.000 claims abstract description 29
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims abstract description 28
- 230000008591 skin barrier function Effects 0.000 claims abstract description 28
- 230000008439 repair process Effects 0.000 claims abstract description 25
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 29
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 24
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 239000003614 peroxisome proliferator Substances 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 208000003251 Pruritus Diseases 0.000 claims description 10
- 230000007803 itching Effects 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 10
- 230000001932 seasonal effect Effects 0.000 claims description 9
- 230000008961 swelling Effects 0.000 claims description 7
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical group Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000008092 positive effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 102000023984 PPAR alpha Human genes 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 229940011399 escin Drugs 0.000 description 3
- 229930186222 escin Natural products 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001126 phototherapy Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000013215 result calculation Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- YPUZOECTETYPRF-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine-2-carboxylic acid Chemical compound OC(=O)C1NCC=CN1 YPUZOECTETYPRF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206595 Halomonas elongata Species 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 108010044210 PPAR-beta Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Abstract
The application discloses a skin care composition and application thereof, wherein the skin care composition comprises ectoine and raspberry ketone, the mass ratio of the ectoine to the raspberry ketone is 10:1-1:15, and the skin care composition has positive effect on promoting skin barrier repair.
Description
Technical Field
The application relates to the technical field of cosmetics, in particular to a skin care composition and application thereof.
Background
In the case of damaged skin barriers (e.g., sensitive skin, atopic dermatitis, acne, etc.), it is necessary to reconstruct a perfect physical barrier and immune barrier, which is mainly achieved by accelerating the formation of epidermal barrier, promoting the maturation of epidermal functions, and inhibiting skin inflammatory reactions, etc.
Peroxisome proliferator activated receptors (peroxisome proliferators-activated receptors, PPARs) are capable of modulating a variety of metabolic processes within cells, and PPARs include three subtypes of PPARα, PPARβ/δ, and PPARγ. PPARα plays a key role in the skin barrier repair process, and promotes its expression, which is beneficial to barrier recovery of consumers with weak skin, seasonal sensitivity, and symptoms such as redness, swelling, itching, etc.
TNF-alpha is a pro-inflammatory cytokine produced mainly by macrophages and monocytes, which stimulates the release of other inflammatory factors, exacerbates the inflammatory response, and causes symptoms such as redness, pain, itching, etc. in the skin. Meanwhile, the skin barrier function may be damaged, so that the skin is easily stimulated by the outside, and the problems of sensitivity, dryness, desquamation and the like are caused. TNF- α overexpression may also exacerbate the extent of barrier damage, contributing to exacerbation of acne inflammation and exacerbation of rosacea redness.
Raspberry ketone can promote the expression of peroxisome proliferator-activated receptors (peroxisome proliferators-activated receptors, PPARs) and inhibit the expression of inflammatory factors, thereby repairing damaged skin barriers. However, how to achieve similar or better effects in the case of reducing the recommended amount of raspberry ketone in cosmetics is a technical problem to be solved in the art.
Disclosure of Invention
The inventors of the present application have unexpectedly found that both exendin and raspberry ketone have different degrees of effects of promoting the expression of peroxisome proliferator-activated receptors (peroxisome proliferators-activated receptors, PPARs) and inhibiting the expression of inflammatory factors at the same amount, and that the effect of raspberry ketone is more superior to that of exendin.
Further, the two are combined according to a certain proportion, so that the combined substances can obtain similar or better effect with higher content of raspberry ketone under the condition of using less amount of raspberry ketone, thereby completing the invention.
The specific technical scheme of the application is as follows:
1. a skin care composition comprising ectoine and raspberry ketone in a mass ratio of 10:1 to 1:15.
2. The skin care composition according to item 1, wherein the mass ratio of the ectoin to the raspberry ketone is 1:4-12.
3. The skin care composition according to any one of claims 1-2, wherein the skin care composition further comprises a cosmetically acceptable adjuvant.
4. Use of the skin care composition of any one of items 1-3 as a peroxisome proliferator activated receptor (peroxisome proliferators-activated receptors, PPARs) expression promoter and/or as an inflammatory factor expression inhibitor.
5. The use according to item 4, wherein the peroxisome proliferator activated receptor is PPAR- α and the inflammatory factor is TNF- α.
6. The use according to item 4 or 5, wherein the composition is for promoting skin barrier repair.
7. The use of item 6, wherein promoting skin barrier repair comprises promoting skin barrier repair in a population having weak skin, seasonal sensitivity, and/or susceptibility to redness and swelling, itching.
8. Use of ectoin as an expression enhancer for peroxisome proliferator-activated receptors (peroxisome proliferators-activated receptors, PPARs).
9. The use according to item 8, wherein the peroxisome proliferator activated receptor is PPAR- α.
10. The use according to item 8 or 9, said ectoin being for promoting skin barrier repair, preferably said promoting skin barrier repair comprising promoting skin barrier repair in a population having weak skin, seasonal sensitivity and/or susceptibility to redness, itching.
ADVANTAGEOUS EFFECTS OF INVENTION
The ectoin or raspberry ketone has the functions of promoting the expression of peroxisome proliferator-activated receptors (peroxisome proliferators-activated receptors, PPARs) and inhibiting the expression of inflammatory factors, thereby being beneficial to promoting the repair of skin barriers, and particularly having good effects on the repair of skin barriers of people with weak skin, seasonal sensitivity and/or susceptibility to redness, swelling and itching.
Further, the combination of ectoin and raspberry ketone can achieve similar or better effects than raspberry ketone alone.
Drawings
FIG. 1 is a bar graph showing the relative expression levels of PPAR-alpha genes.
FIG. 2 is a bar graph showing the relative expression levels of TNF- α gene.
Detailed Description
The embodiments described below are described in detail for the present application. While specific embodiments of the present application are shown, it should be understood that the present application may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.
It should be noted that certain terms are used throughout the description and claims to refer to particular components. Those of skill in the art will understand that a person may refer to the same component by different names. The specification and claims do not identify differences in terms of components, but rather differences in terms of the functionality of the components. As referred to throughout the specification and claims, the terms "include" or "comprising" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description hereinafter sets forth the preferred embodiment for carrying out the present application, but is not intended to limit the scope of the present application in general, as the description proceeds. The scope of the present application is defined by the appended claims.
Composition and method for producing the same
One aspect of the present application relates to compositions, which "compositions" include, but are not limited to, simultaneous or sequential use of the ingredients, provided that the effects described herein are achieved. The term "simultaneous use" includes use together in the same formulation or separately in different formulations. The "sequentially used" includes sequentially use in different preparations, and there is no limitation on the order of sequential use.
The application provides a skin care composition comprising ectoine and raspberry ketone, wherein the mass ratio of the ectoine to the raspberry ketone is 10:1-1:15, preferably 1:4-12.
In the present application, escin (also known as tetrahydropyrimidinecarboxylic acid) is an amino acid derivative, and escin is derived from halophil (Halomonas Elongata), so escin is also referred to as "salt-tolerant bacteria extract". Under extreme conditions of high salt, high temperature, and high ultraviolet radiation, escitalopram protects halophilic bacteria from injury.
In the present application, the raspberry ketone, also known as raspberry ketone, is an organic compound of formula C 10 H 12 O 2 Molecular weight 164.22.
In the present application, the mass ratio of the ectoin and the raspberry ketone (m Ikeduoyin :m Raspberry ketone ) May be 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, etc.
In some embodiments, the composition further comprises a skin care acceptable adjuvant.
The auxiliary materials are not limited in any way, and are auxiliary materials conventionally used in the art.
The skin care compositions described herein promote the relative expression of peroxisome proliferator activated receptors (peroxisome proliferators-activated receptors, PPARs) and reduce the relative expression of inflammatory factors, indicating that the compositions described herein have a positive effect on repair of damaged skin barriers.
In some embodiments, the peroxisome proliferator activated receptor is PPAR- α and the inflammatory factor is TNF- α.
In some embodiments, the skin care compositions described herein are used to promote skin barrier repair.
In some embodiments, the promoting skin barrier repair comprises promoting skin barrier repair in a population with weak skin, seasonal sensitivity, and/or susceptibility to redness, swelling, itching.
In some embodiments, the skin care compositions described herein are useful for promoting keratinocyte differentiation, promoting epidermal lipid synthesis, modulating inflammatory response, promoting collagen production, reducing active oxygen formation under uv induction, preventing uv damage.
The application also provides the use of ectoin as an expression enhancer for peroxisome proliferator-activated receptors (peroxisome proliferators-activated receptors, PPARs).
The application also provides the use of raspberry ketone as an expression promoter for peroxisome proliferator-activated receptors (peroxisome proliferators-activated receptors, PPARs).
In some embodiments, the peroxisome proliferator activated receptor is PPAR- α and the inflammatory factor is TNF- α.
In some embodiments, the ectoin is used to promote skin barrier repair.
In some embodiments, the promoting skin barrier repair comprises promoting skin barrier repair in a population with weak skin, seasonal sensitivity, and/or susceptibility to redness, swelling, itching.
In some embodiments, the promoting skin barrier repair comprises promoting skin barrier repair in a population with weak skin, seasonal sensitivity, and/or susceptibility to redness, swelling, itching.
In some embodiments, the skin care compositions described herein are useful for promoting keratinocyte differentiation, promoting epidermal lipid synthesis, modulating inflammatory response, promoting collagen production, reducing active oxygen formation under uv induction, preventing uv damage.
Examples
The materials used in the test and the test methods are generally and/or specifically described herein, and in the examples which follow,% represents wt%, i.e., weight percent, unless otherwise specified. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge. The experimental materials used in the preparation examples and experimental examples are shown in table 1, and the experimental facilities are shown in table 2.
Table 1 preparation examples and experimental materials used in experimental examples
Table 2 table of experimental facilities used in preparation examples and experimental examples
| Main equipment | Manufacturer' s&Model number |
| Super clean bench | Suzhou Sujing purification technologies Co., ltd., SW-CJ-2D |
| Inverted microscope | OLYMPUS，CKX53 |
| Precision electronic balance | OHAUS，CP214 |
| CO 2 Incubator | Thermo，3111 |
| Ultraviolet lamp phototherapy instrument | Keno medical instruments Co., ltd., KN-4006BL1 |
| Enzyme label instrument | Tecan，SPARK |
| Fluorescent quantitative PCR instrument | BioRad，CFX Connect |
Preparation example
1. Preparing a complete culture medium solution
DMEM basal medium, FBS fetal bovine serum, PS diabody solution were mixed at a mass ratio of 89:10:1.
2. Preparation of sample sets
The exendin and raspberry ketone powder was weighed and dissolved in the complete medium solution to form the test object working solution, wherein the concentrations of exendin and raspberry ketone are shown in table 3, and the numbers are 1-11.
3. Preparation of positive control group
The positive drug WY-14643 was weighed and dissolved in the complete medium solution to form a test working solution, wherein the concentration of WY-14643 is shown in Table 3.
4. Blank control and negative control were prepared
The blank control group and the negative control group are complete culture medium solutions.
TABLE 3 mass ratio of Ikeduo and raspberry ketone and corresponding concentration table
| case | Mass ratio of ectoin to raspberry ketone | Working fluid for test object |
| Blank Control (BC) | / | / |
| Negative Control (NC) | / | / |
| Positive Control (PC) | / | 10μM WY-14643 |
| 1 | 1:0 | 600 μg/mL of ectoin |
| 2 | 0:1 | 600 μg/mL raspberry ketone |
| 3 | 20:1 | 571 μg/mL of ectoin; 29 mug/mL raspberry ketone |
| 4 | 9:1 | 540 μg/mL of ectoin; 60 mug/mL raspberry ketone |
| 5 | 1.5:1 | 360 μg/mL of ectoin; 240 mug/mL raspberry ketone |
| 6 | 1:1 | 300 μg/mL of ectoin; 300 mug/mL raspberry ketone |
| 7 | 1:2.5 | 171 μg/mL of ectoin; 429 μg/mL raspberry ketone |
| 8 | 1:4 | 120 μg/mL of ectoin; 480 μg/mL raspberry ketone |
| 9 | 1:9 | 60 μg/mL of ectoin; 540 μg/mL raspberry ketone |
| 10 | 1:12 | 46 μg/mL of ectoin; 554 μg/mL raspberry ketone |
| 11 | 1:20 | 29 μg/mL of ectoin; 571 μg/mL raspberry ketone |
Experimental example 1 determination of relative expression level of PPAR-alpha
1) Cell inoculation: according to 6X 10 5 Seeding Density of individual/well keratinocytes were seeded into 6-well plates, incubator (37 ℃, 5% CO) 2 ) And incubated for 24h.
2) Preparing liquid: test object working solutions were prepared according to the test protocols (table 3), respectively.
3) And (3) molding: according to the test group, the sample group, the positive control group, and the negative control group were exposed to an ultraviolet lamp phototherapy instrument (wavelength 280-320nm,80mJ/cm 2 ) UVB irradiation was performed and the blank group was not subjected to any treatment.
4) Administration: the dosing was performed in groups according to the test protocol of table 3, 1mL per well, 3 duplicate wells per group. After the completion of the administration, the 6-well plate was placed in an incubator (37 ℃, 5% CO) 2 ) Is cultured for 24 hours.
5) Collecting cells: after 24h of incubation, the cell supernatants were collected, washed twice with 1 mL/well of D' Hanks buffer, and the lysed cells were blown off and the samples were collected.
6) And (3) gene expression detection: RNA-Quick Purification Kit is processed on cells and then samples are collected, and RNA extraction, reverse transcription and fluorescent quantitative PCR operations are carried out according to the instruction of the kit, and 2- △△Ct The method performs result calculation to obtain detection results, which are shown in table 4.
7) Results statistical analysis: the comparison between the groups uses t-test statistical analysis with a confidence of 95%, and the results are shown in fig. 1, wherein when there are completely different letters for the two groups of results, it indicates that there is a statistically significant difference between the two groups of results, and when the letters of the two groups of results are completely the same, it indicates that there is no statistical difference between the two groups, and the following is the same.
Experimental example 2 determination of relative expression level of TNF-alpha
1) Cell inoculation: according to 6X 10 5 Seeding Density of individual/well keratinocytes were seeded into 6-well plates, incubator (37 ℃, 5% CO) 2 ) And incubated for 24h.
2) Preparing liquid: test object working solutions were prepared according to the test protocols (table 3), respectively.
3) And (3) molding: according to the test group, the sample group, the positive control group, and the negative control group were exposed to an ultraviolet lamp phototherapy instrument (wavelength 280-320nm,80mJ/cm 2 ) UVB irradiation was performed and the blank group was not subjected to any treatment.
4) Administration: the dosing was performed in groups according to the test protocol of table 3, 1mL per well, 3 duplicate wells per group. After the completion of the administration, the 6-well plate was placed in an incubator (37 ℃, 5% CO) 2 ) Is cultured for 24 hours.
5) Collecting cells: after 24h of incubation, the cell supernatants were collected, washed twice with 1 mL/well of D' Hanks buffer, and the lysed cells were blown off and the samples were collected.
6) And (3) gene expression detection: RNA-Quick Purification Kit is processed on cells and then samples are collected, and RNA extraction, reverse transcription and fluorescent quantitative PCR operations are carried out according to the instruction of the kit, and 2- △△Ct The method performs result calculation to obtain detection results, which are shown in table 4.
7) Results statistical analysis: the comparison between groups was performed using t-test statistical analysis with a 95% confidence, and the results are shown in FIG. 2.
TABLE 4 relative expression levels of PPAR-alpha and TNF-alpha
The above description is only of the preferred embodiments of the present application and is not intended to limit the present application in any way, and any person skilled in the art may make modifications or alterations to the disclosed technical content to the equivalent embodiments. However, any simple modification, equivalent variation and variation of the above embodiments according to the technical substance of the present application still fall within the protection scope of the technical solution of the present application.
Claims (10)
1. A skin care composition comprising ectoine and raspberry ketone in a mass ratio of 10:1 to 1:15.
2. The skin care composition according to claim 1, wherein the mass ratio of the ectoin to the raspberry ketone is 1:4-12.
3. The skin care composition according to any one of claims 1-2, wherein the skin care composition further comprises a cosmetically acceptable adjuvant.
4. Use of a skin care composition according to any one of claims 1 to 3 as a peroxisome proliferator activated receptor (peroxisome proliferators-activated receptors, PPARs) expression promoter and/or as an inflammatory factor expression inhibitor.
5. The use according to claim 4, wherein the peroxisome proliferator activated receptor is PPAR- α and the inflammatory factor is TNF- α.
6. The use according to claim 4 or 5, the composition for promoting skin barrier repair.
7. The use of claim 6, said promoting skin barrier repair comprising promoting skin barrier repair in a population having weak skin, seasonal sensitivity, and/or susceptibility to redness, swelling, and itching.
8. Use of ectoin as an expression enhancer for peroxisome proliferator-activated receptors (peroxisome proliferators-activated receptors, PPARs).
9. The use according to claim 8, wherein the peroxisome proliferator activated receptor is PPAR- α.
10. The use of claim 8 or 9, the ectoin for promoting skin barrier repair, preferably the promoting skin barrier repair comprises promoting skin barrier repair in a population with weak skin, seasonal sensitivity and/or susceptibility to redness, itching.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311445031.3A CN117323250A (en) | 2023-11-01 | 2023-11-01 | Skin care composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311445031.3A CN117323250A (en) | 2023-11-01 | 2023-11-01 | Skin care composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117323250A true CN117323250A (en) | 2024-01-02 |
Family
ID=89277397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311445031.3A Pending CN117323250A (en) | 2023-11-01 | 2023-11-01 | Skin care composition and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117323250A (en) |
-
2023
- 2023-11-01 CN CN202311445031.3A patent/CN117323250A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111088174B (en) | Saccharomycetes Fungiensis with oxidation resistance and whitening effect and application thereof | |
| WO2019004684A2 (en) | Cosmetic composition for reducing skin wrinkle or moisturizing skin, comprising nano-sized kimchi lactic acid bacteria | |
| CN115554226B (en) | Multi-strain fermentation filtrate and preparation method and application thereof | |
| CN114081901B (en) | Probiotic composition, preparation method and application thereof | |
| WO2006064974A1 (en) | Skin whitening preparation for external use, whitening preparation, whitening method and method of producing skin whitening preparation for external use | |
| CN113318037A (en) | Microbial fermentation method for increasing content of active ingredients in peony and application | |
| KR20170143053A (en) | Cosmetic composition for improving anti-oxidation, anti-wrinkle and moisturizing comprising fermented product of used water from washing rice and preparation method of the same | |
| CN115670964B (en) | Preparation method, composition and application of hydrolyzed ginseng saponin composition with soothing and repairing effects | |
| CN115181695A (en) | Lactobacillus plantarum5b4m2 and application thereof | |
| WO2021093425A1 (en) | Root of membranous milkvetch-paecilomyces cicadae fermentative bacterium fermentation substance and application thereof | |
| CN117323250A (en) | Skin care composition and use thereof | |
| JP6169170B2 (en) | Saccharide fraction from wheat, isolation method and field of use of the invention | |
| Kennedy et al. | ‘Water Structure’versus ‘Radical Scavenger’theories as explanations for the suppressive effects of DMSO and related compounds on radiation-induced transformation in vitro | |
| KR20180111738A (en) | Cosmetic composition for improving anti-oxidation, anti-wrinkle and moisturizing comprising fermented product of used water from washing rice and preparation method of the same | |
| CN115197856B (en) | Cordyceps militaris strain and application thereof | |
| CN115054556B (en) | Composition for repairing photodamage and application thereof | |
| CN115261273A (en) | Lactobacillus jensenii and application thereof | |
| CN115414290A (en) | Traditional Chinese medicine composition with moisturizing, antioxidant and anti-inflammatory effects and preparation and application thereof | |
| TW202102244A (en) | Plant fermented product and uses thereof for protecting liver, improving mitochondrial activity of cells, anti-oxidation, anti-aging, and increasing expression of cct gene, pink1 gene, mrps5 gene, foxo gene and ubl5 gene | |
| CN111939182A (en) | Application of ginkgo callus extract and method for culturing ginkgo callus | |
| Junuda et al. | Toothpaste Formulation Ethanol Extract Mangosteen Peel (Garcinia mangostana L.) and Test Activity Against Candida albicans | |
| Lee et al. | A novel sophorolipids extraction method by yeast fermentation process for enhanced skin efficacy | |
| CN111995603B (en) | Sesquiterpene compound with antioxidant activity | |
| CN114645070B (en) | Preparation method of hexose-6-phosphoric acid composition and application thereof in cosmetics | |
| CN113750018B (en) | Plant composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |